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CObjective: To estimate the prevalence of constipation concomitant to
opioid treatment and related resource use and costs from the private
payer perspective. Methods: In this retrospective database analysis,
atients receiving opioid therapy were identified from a longitudinal
nsurance claims database. An algorithmwas used to identify patients
eceiving opioid therapy with coincident constipation-related claims
ccording to ICD-10 codes, targeted procedures, and opioid use criteria.
esource use and costs were determined for these individuals and
omparedwith patients receiving opioid therapywithout constipation,
ithout opioid therapy with constipation, and without both condi-
ions. Results were compared using analysis of variance with a signif-
cance level of 0.05.Results: A total of 23,313 patientswere classified as
pioid-treated patients (2.2%) and 6678 of them had events related to
onstipation (29.0%). Compared with opioid-treated patients without
onstipation, incrementalmean total costs permonth per patient were
61.18 BRL (P  0.001). The average cost per month for opioid-related O
d
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m Pfi
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ledge
al So
oi:10.1016/j.jval.2011.05.019onstipation patients was 787.84 BRL, significantly higher than other
atients (P  0.001 for all comparisons). Among cancer patients, 24.4%
as receiving opioids and 27.0% of those had constipation-related
laims. As expected, the opioid therapy prevalence was significantly
igherwhen compared to all patients (2.2% vs. 24.4%, P 0.001). Cancer
atients had, in average, higher costs than did noncancer patients in all
our subgroups. Conclusions: Patients with constipation coincident
ith opioid treatment exhibited a significantly higher economic bur-
en thandid patientswithout the condition. These results indicate that
educing opioid-induced constipation could lead to potential cost sav-
ngs for the health care system.
eywords: analgesics, constipation, costs and cost analysis, drug
oxicity, opioid.
opyright © 2011, International Society for Pharmacoeconomics and
utcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Opioids are the mainstay therapy for patients with moderate to
severe pain. According to the Brazilian Society for Study of Pain [1],
he prevalence of chronic pain is about 30%within the country and
oncancer pain is responsible for 60% to 70%of chronic pain cases.
or these patients opioid treatment must be very carefully moni-
ored and is generally reserved for refractory cases. Thus, it is
stimated that about 10% of patients with chronic pain will even-
ually receive opioid treatment. Of these, 70% had moderate pain,
ndicating the use of a weak opioid and 30% strong or very strong
ain with indication of strong opioids [2]. Pain is present in 30% of
ancer patients undergoing chemotherapy and in 60% to 90% of
hose with advanced cancer [3].
Although effective in pain management [4], opioid therapy is
requently complicated by side effects [5]. With continued use,
atients usually develop tolerance to those side effects, except
onstipation, which is the most common and usually the most
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ublished by Elsevier Inc.ebilitating side effect reported by patients, with a median fre-
uency of 30% among noncancer patients (range 12%–52%) [6]. The
prevalence in cancer patients is even higher [7], reaching 63% [8],
and laxatives are required by 87% of terminally ill cancer patients
taking oral strong opioids and by 74% of those receiving weak
opioid therapy [9,10].
Constipation is also associated with a serious negative ef-
fects on patients’ health-related quality of life (HRQoL) and on
society in terms of health care resource use and work produc-
tivity loss [11]. Patients with constipation have more hospital
admissions, emergency room visits, home health services,
nursing home care, physician visits, and laboratory tests, as
well as higher mean all-cause costs for emergency, physician
visits, nursing facilities, home health care, and prescription
drug services compared to patients without constipation [12].
Further, it is known that constipation usually persists for as
long as opioid therapy is administered [8].
In Brazil, opioid consumption was estimated at 1.1520 mg per
capita, showing an average prescription below the world average
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S79V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) S 7 8 – S 8 1consumption (5.5708mg per capita) and indirect evidence of inad-
equate pain control in the country [13]. Despite these variations, a
large number of patients are currently receiving opioid therapy for
chronic pain worldwide. To date, no studies evaluating the prev-
alence of constipation in patients using opioids have been pub-
lished in Brazil; neither their related management resource use
nor costs.
This study aimed to estimate the prevalence of constipation
concomitant to opioid treatment and to compare resource use and
costs in opioid-treated patients with and without constipation,
from the private payer perspective in Brazil.
Methods
Data source
Patients receiving opioid therapy were identified from a longitudi-
nal insurance claims database (Axismed Database) consisting in
1,057,033 individuals observed during a 35-month period (Decem-
ber 2004 to December 2007). This database comprises about 3% of
the population covered by health insurance plans across all five
geographic regions in Brazil (national coverage). Its general data
include patient demographics, medical claims, and enrollment
date. Medical claims information includes date, type of procedure,
provider specialty, amount paid, and diagnosis code using Inter-
national Classification of Diseases, 10th revision (ICD-10) [14]. Av-
rage patient exposition time was 21.84 months.
Study population
An algorithm was developed through evidence-based clinical
rules and expert opinion to identify patients receiving opioid ther-
apy with coincident constipation-related claims according to
ICD-10 codes and constipation-related procedures. Patients were
initially segmented according to the presence of opioid therapy
records. To be subsequently classified as a patient with constipa-
tion concomitant to opioid therapy, patients with evidence of opi-
oid analgesics use had to meet at least one of the following eligi-
bility criteria: at least one medical claim with an ICD-10 code
potentially related to constipation (i.e., K59.0, K59.9, or R19.4)
and/or at least one medical procedure potentially related to con-
stipation (e.g., enemas or manual, endoscopic, or surgical fecal
impaction removal).
The individuals in the database were then classified in four
groups: nonopioid-treated without constipation (NONC), nonopi-
oid-treated with constipation (NOWC), opioid-treated without
constipation (ONC), and opioid treated with constipation (OWC).
To ensure more detailed analysis reflecting relevant clinical ques-
tions, individual with oncologic ICD-10 codes were separately an-
alyzed, once opioid therapy and opioid-related constipation prev-
alence is usually higher among cancer patients.
Outcomes measures
Resource use and costs were collected for each individual during
the 35-month follow-up period using a top-down approach [15].
Once individualswere followed for varying amounts of time, these
variables (i.e., total costs, costs segmented by category, and re-
source use segmented by category) were then converted to per
member/per month units dividing the results for all patients by
the person-months of follow-up. Resource use results are pre-
sented as average consumption per month of six claims groups:
outpatient procedures, consultations, tests and therapies, hospi-
talization, emergency department visits, and others. Hospitaliza-
tions are reported as hospital days. Costs were collected as re-
ported in the administrative database, reflecting the amount
effectively paid by eachhealth insurance plan. Costs are presented
in Brazilian reals (BRL), using reference values for 2009. aStatistical analyses
Medical resource use and costs in patients with constipation co-
incident with opioid therapy (OWC) were compared with the out-
comes observed in the other three groups (NONC, NOWC, and
ONC). The permember permonth outcomeswere compared using
analysis of variance, with corresponding P values reported with a
significance level of 0.05. If the analysis of variance test indicated
a statistically significant difference, further post hoc analyses
were performed. SAS (version 9, 2002, SAS Institute Inc., Cary, NC)
statistical software was used to perform all analyses.
Results
All patients
In our study, 23,313 patients were classified as opioid-treated pa-
tients (2.2% of total population) and 6678 of them had events or
ICD-10 codes related to constipation, resulting in a constipation
prevalence of 29.0% among opioid-treated patients. Themean age
of OWC patients was 51.58  19.35 years, 65.0% was women, 1.0%
had cancer diagnosis, and the mean follow-up per individual
ranged from 20.03 to 24.44 months in each group. Table 1 in Sup-
plemental Materials found at: doi:10.1016/j.jval.2011.05.019 sum-
marizes the baseline characteristics of the study sample, includ-
ing average costs (mean  SD) and resource use (mean  SD) per
patient during the follow-up. Mean cost per patient ranged from
2,122 BRL (NONC) to 17,206 BRL (OWC) and the average cost per
patient for the entire sample was 2,486 BRL.
Table 2 in Supplemental Materials found at: doi:10.1016/j.
jval.2011.05.019 compares average cost and resource use per
month of OWC patients with the other three subgroups. Com-
pared to opioid-treated patients without constipation, average in-
cremental costs per month per patients with the condition were
261.18 BRL (P  0.001). The average cost per month for OWC pa-
tients was 787.84 BRL, significantly higher than ONC (526.66 BRL),
NOWC (284.47 BRL), andNONCpatients (90.17 BRL) (P 0.001 for all
comparisons). Patients with claims related to both conditions had
significantly more days in hospital per month (0.25 vs. 0.497, P 
0.001), outpatient office visits (1.04 vs. 1.59, P  0.001), outpatient
procedures (4.69 vs. 14.05, P 0.001) and tests and therapies (31.95
vs. 36.66, P  0.001) than did patients without opioid-related con-
stipation claims.
Cancer patients
Cancer patientswere considered as a separate subgroup due to the
expected higher prevalence of both conditions (opioid therapy and
constipation) among those individuals. Oncology ICD-10 codes
were identified for 9873 individuals, representing 1.0% of the total
population. Among those, 24.4% was receiving opioid therapy and
27.0% of those had constipation-related claims. As expected, the
opioid therapy prevalence was significantly higher among cancer
patientswhen compared to all patients (2.21% vs. 24.4%, P 0.001).
mong opioid-treated patients the prevalence of constipationwas
imilar in both groups (29.0% for all patients and 27.0% for cancer
atients), regardless of cancer status. Table 3 in Supplemental Ma-
erials found at: doi:10.1016/j.jval.2011.05.019 presents the costs
nd resource use results for the cancer population, considering
he same subgroups previously described. Cancer patients had, on
verage, higher costs than did noncancer patients in all four con-
tipation and opioid status categories. The absolute difference be-
ween ONC and OWC patients, however, remains stable when
ompared to the observed difference in all patients’ analysis
263.21 BRL vs. 261.18 BRL, respectively). When segmented costs
ere analyzed, OWC patients resulted in higher costs due to tests
nd therapies and hospital days, but did not for other categories.
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Opioid-related constipation hasmultidimensional influences on a
patient’s health status and consequently results in complex bur-
dens for health care systems. To relieve constipation, patients of-
ten abandon their opioid medication, potentially impairing anal-
gesia. Therefore, the burden of constipation can be not only from
the direct influence of its symptoms on HRQoL and constipation-
related health care resources consumption, but also frommedical
resources to relieve the pain and the side effects of treatments
taken to relieve the condition.
The observed prevalence of constipation in our sample was
quite similar to data reported by a meta-analysis focused in older
patients without cancer (29.03% vs. 30.00%, respectively) [1]. The
subgroup analysis of cancer patients showed a slightly lower prev-
alence (27.0%), which is different than results previously de-
scribed, achieving 63% [8]. These published data refer to the higher
rate reported by hospice cancer patients in the United States. A
study published in 2001 [16] with 593 cancer patients treated by a
pain service showed a 23% prevalence of constipation and this
symptom was assessed as being frequently caused by the analge-
sic regimen. Furthermore, much of the variation in the frequency
of constipation in patients treated with oipiods can be attributed
to study design and population heterogeneity: age, sex, base pa-
thology, type of opioid administered, its dose and duration, and
subjective perception of constipation.
Our findings indicated that, on average, opioid-treated patients
were significantly more costly than patients without opioid-re-
lated events, and patients with constipation-related claims re-
sulted in higher medical costs than those without constipation.
The incremental costs observed for patients with constipation-
related claims coincident with opioid therapy, when compared to
opioid-treated nonconstipated patients, were about 260 BRL per
individual per month either for cancer patients or for the entire
sample. The similar findings for both subgroups can indicate that
the observed difference probably reflects the actual absolute dif-
ference in costs due to constipation related to opioid therapy.
The effects of constipation in patients using opioids has al-
ready been studied in other countries showing similar results. A
literature review was conducted to identify national and inter-
national cost-of-illness and prevalence studies addressing the
burden of opioid-related constipation using a mix of controlled
vocabulary and free text terms for constipation, opioid therapy,
prevalence, and costs. PubMed and LILACS databases were
searched and only US and European studies were found [7,9–
12,17–22].
In the United States, Bell et al. [11] evaluated the effects of
opioid-induced constipation on health care resource use, work
productivity, andHRQoLwith data from2430 individuals, ofwhom
359 reported constipation. Opioid-induced constipation patients
reported significantly more physician visits and alternative care
visits. Significantly greater productivity loss and significantly
lower HRQoLwere observed in the constipated group, both signals
of a negative influence on individuals’ health status.
Iyer et al. [12] also compared the opioid use patterns, resource
use, and costs of 39,485 US patients receiving opioid therapy who
had constipation with those who did not. Patients with constipa-
tion had statistically significant higher resource use and all-cause
costs compared to patients without constipation. Those studies
showed that opioid-related constipation has a significant influ-
ence on costs and resource use in developing countries and it
seems reasonable to believe that this association between higher
health care resource consumption and opioid-related constipa-
tion could be observed in other similar countries, but there is still
a lack of evidence concerning this issue in Brazil or Latin America.
As stated before, average opioid prescription in Brazil is consid-
ered below the world average consumption and this is indirectevidence of inadequate pain control in the country [13]. In addi-
tion, resource use and medical costs are directly related to pa-
tients’ access to the health care system, reimbursement and
coverage processes, local therapeutic patterns, and clinical
guidelines, all of which are expected to be significantly different
across countries, particularly if they have different health care
system organizations.
Study limitations include potential selection bias due to retro-
spective analysis of administrative database, misclassification of
patients (ICD-10 codes are not homogeneously used in Brazilian
clinical practice, particularly for general conditions such as con-
stipation), and the lack of more detailed baseline clinical informa-
tion in the original database to provide clinical and demographic
variables that could be used to control for confounders. Trying to
minimize those limitations, the opioid-treated patientswere com-
pared with nonopioid-treated patients and cancer patients were
separately analyzed. We hypothesized that higher prevalence of
cancer among OWC patients could lead to higher costs due to
cancer treatments (e.g., chemotherapy, radiation therapy, and
surgery) and not directly to opioid-related constipation. These hy-
potheses can be rejected once the same difference in costs was
observed when only cancer patients were compared. In addition,
opioid-treated patients are more likely to be in palliative care (i.e.,
not receiving high-cost cancer treatment).
Retrospective claims database studies are still a novel field of
research in Health Economics and Outcomes Research in Brazil
and there is a recognizable absence of data concerning patients
with private health care plans coverage. Our findings provided the
first local overview of the burden associated to opioid-related con-
stipation in Brazil. Further research is needed to validate those
findings through primary data collection, preferably in a prospec-
tive fashion.
Conclusions
Patients with constipation coincident with opioid treatment ex-
hibited a significantly higher economic burden than did patients
without the condition. These results indicate that reducing opioid-
induced constipation could lead to potential cost savings for the
health care system.
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